InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions

摘要

Author contributions: The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors, take responsibility for the integrity of the work as a whole, contributed to the writing and reviewing of the manuscript, and have given final approval for the version to be published. All authors had full access to the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. A Bourdin, G Criner, G Devouassoux, M Dransfield, DMG Halpin, JM Echave-Sustaeta María-Tomé, NA Hanania, R Kalhan, and TM Siler contributed to the acquisition of data and data analysis and interpretation. MK Han, CE Jones, P Lange, S Lettis, DA Lomas, N Martin, FJ Martinez, H Quasny, L Sail, D Singh, B Thomashow, H Watz and R Wise contributed to data analysis and interpretation. D.A. Lipson contributed to study conception and design, and data analysis and interpretation.